Pharmacokinetics of liquiritigenin and its two glucuronides, M1 and M2, in rats with acute hepatitis induced byd-galactosamine/lipopolysaccharide or CCl4
Authors:
- H.E. KangHKH.E. Kang
- Y.W. KimYKY.W. Kim
- S.I. SohnSSS.I. Sohn
- S.R. BaekSBS.R. Baek
- J.W. LeeJLJ.W. Lee
- S.G. KimSKS.G. Kim
- I. LeeILI. Lee
- M.G. LeeMLM.G. Lee
- 18 March 2010
- journal article
- Published by Taylor & Francis in Xenobiotica
- Vol. 40 (6) , 424-436
Abstract
Cytoprotective effects of liquiritigenin (LQ) against liver injuries have been reported, but its pharmacokinetics has not been studied in acute hepatitis. Thus, pharmacokinetics of LQ and its two conjugated glucuronide metabolites: 4'-O-glucuronide (M1) and 7-O-glucuronide (M2), in rats with acute hepatitis induced by d-galactosamine/lipopolysaccharide (GalN/LPS) rats or carbon tetrachloride-treated (CCl(4)-treated) rats were evaluated. LQ was administered intravenously (20 mg kg(-1)) and orally (50 mg kg(-1)) to control GalN/LPS and CCl(4)-treated rats. Expression of uridine 5'-diphospho-glucuronosyltransferases 1A (UGT1A) and in vitro metabolism of LQ in hepatic and intestinal microsomes were also measured. After intravenous administration of LQ, area under the plasma concentration-time curve (AUC) of LQ in GalN/LPS rats was significantly smaller than that in controls due to faster non-renal clearance, as a result of its greater free fraction in plasma and faster hepatic blood flow rate than the controls. In CCl(4)-treated rats, the AUC(M1, 0-8 h)/AUC(LQ) and AUC(M2, 0-8 h)/AUC(LQ) ratios were significantly greater than the controls due to decrease in biliary excretion of M1 and M2. However, no significant pharmacokinetic changes were observed in both acute hepatitis rats after oral administration due to comparable intestinal metabolism of LQ. Modification of oral dosage regimen of LQ may not be necessary in patients with acute hepatitis; but human studies are required.Keywords
This publication has 28 references indexed in Scilit:
- Pharmacokinetics of Liquiritigenin in Mice, Rats, Rabbits, and Dogs, and Animal Scale-UpJournal of Pharmaceutical Sciences, 2009
- Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effectXenobiotica, 2009
- Liquiritigenin, an aglycone of liquiritin in Glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sulfoximineChemico-Biological Interactions, 2006
- Hepatic circulation: Potential for therapeutic interventionPharmacology & Therapeutics, 1990
- The effects of valproate on plasma concentration of phenytoin in normal and D-galactosamine-treated rats.Chemical and Pharmaceutical Bulletin, 1987
- Determination of hepatic uridine 5′-diphosphoglucuronic acid concentration by conjugation with diethylstilbestrolJournal of Pharmacological Methods, 1982
- Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curveJournal of Pharmacokinetics and Biopharmaceutics, 1978
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Galactosamine hepatitis: Key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death1974
- Effect of carbon tetrachloride on the metabolism, storage, and excretion of sulfobromophthaleinToxicology and Applied Pharmacology, 1968